1. Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol Rep. 2006. 8:131–138.
2. Knuuti J, Sipola P. Is it time for cardiac innervation imaging? Q J Nucl Med Mol Imaging. 2005. 49:97–105.
3. Kang DY. Clinical application of I-123 MIBG cardiac imaging. Korean J Nucl Med. 2004. 38:331–337.
4. Ha JW, Lee JD, Chung N, et al. Iodine-123-metaiodobenzylguanidine myocardial scintigraphy in patient with dilated cardiomyopathy: correlation between myocardial MIBG uptake and echocardiographic parameter. Korean Circ J. 1996. 26:651–666.
5. Ha JW, Lee JD, Jang Y, et al. Assessment of cardiac sympathetic neuronal integrity using Iodine-123 metaiodobenzylguanidine myocardial scintigraphy and its clinical efficacy as a new noninvasive screening test for the diagnosis of coronary artery spasm. Korean Circ J. 1998. 28:183–193.
6. Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001. 42:1757–1767.
7. Imamura Y, Fukuyama T. Prognostic value of myocardial MIBG scintigraphy findings in patients with cardiomyopathy: importance of background correction for quantification of MIBG activity. Ann Nucl Med. 2002. 16:387–393.
8. Gill JS, Hunter GJ, Gane J, Ward DE, Camm AJ. Asymmetry of cardiac 123I- meta-iodobenzyl-guanidine scans in patients with ventricular tachycardia and a "clinically normal" heart. Br Heart J. 1993. 69:6–13.
9. Mitrani RD, Klein LS, Miles WM, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol. 1993. 22:1344–1353.
10. Yoshioka K, Gao DW, Chin M, et al. Heterogeneous sympathetic innervation influences local myocardial repolarization in normally perfused rabbit hearts. Circulation. 2000. 101:1060–1066.
11. Ferrans VJ, Hibbs RG, Walsh JJ, Burch GE. Histochemical and electron microscopical studies on the cardiac necroses produced by sympathomimetic agents. Ann N Y Acad Sci. 1969. 156:309–332.
12. Kim SJ, Lee DY, Lee JD, et al. Evaluation of sympathetic innervation in cardiomyopathy with 123I-MIBG. Korean J Nucl Med. 1993. 27:195–202.
13. Gao DW, Talke PO, Dae MW. Effects of reduced sympathetic activity on myocardial metaiodobenzylguanidine (MIBG) washout. J Auton Pharmacol. 2001. 21:159–164.
14. Dae MW, O'Connell JW, Botvinick EH, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 1989. 79:634–644.
15. Turpeinen A, Vanninen E, Magga J, Tuomainen P, Kuusisto J, Sipola P. Cardiac sympathetic activity is associated with elevated levels of proinflammatory cytokines in patients with idiopathic dilated cardiomyopathy. Eur J Nucl Med. 2004. 31:S292.
16. Kyuma M, Nakata T, Hashimoto A, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004. 45:155–163.
17. Maeno M, Ishida Y, Shimonagata T, et al. The significance of 201Tl/123I MIBG (metaiodobenzylguanidine) mismatched myocardial regions for predicting ventricular tachycardia in patients with idiopathic dilated cardiomyopathy. Kaku Igaku. 1993. 30:1221–1229.
18. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988. 78:1192–1199.